Company intelligence / Profile preview

Mozart Therapeutics

Seattle, Washington, United Statesmozart-tx.com ↗

Ownership: Private
Development stage: Other

Overview

Mozart Therapeutics is developing first-in-class CD8 Treg modulators to restore immune balance in patients with autoimmune and inflammatory diseases. The company's approach targets a novel immune pathway to change the course of these diseases.

Therapeutic areas: Immunology
Modalities: CD8 Treg ModulatorsBiologics
Industry: Biotech

Drug pipeline

2 assets

MTX-101

1 more asset in the full pipeline.

Partnerships

Eli Lilly & CompanyMerck & Co., Inc. (via MRL Ventures Fund)Bayer (via Leaps by Bayer)

Beyond the preview

Go deeper on Mozart Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mozart Therapeutics.